PLOS Medicine:大规模研究揭示,人造甜味剂与癌症风险增加有关

2022-03-27 王聪 “生物世界”公众号

肥胖不仅会导致生活不便、运动能力下降,还会带来代谢性疾病和心脑血管疾病,此外,许多研究表明,肥胖与十多种癌症的发病风险增加和预后及生存率降低有关。

随着经济发展和生活水平的提高,在全世界范围内,肥胖已经成为了一个主要公共健康问题。据世界卫生组织(WHO)统计,全球有近20亿人超重或肥胖,从1975到2016年,全球肥胖率翻了近3倍,每年因超重或肥胖导致的死亡高达280万。

肥胖不仅会导致生活不便、运动能力下降,还会带来代谢性疾病和心脑血管疾病,此外,许多研究表明,肥胖与十多种癌症的发病风险增加和预后及生存率降低有关。

为了减少糖对健康的影响以及肥胖的影响,越来越多的人开始使用人造甜味剂代替正常糖类,这些人造甜味剂具有糖类的甜味,却又不产生热量,人们认为其可作为一种健康的饮食方式,因此近年来广受追捧。然而,人造甜味剂对健康的影响仍然存在很大的争议。

2022年3月24日,巴黎第十三大学的研究人员在 PLOS Medicine 期刊发表了题为:Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study 的研究论文。

人造甜味剂的使用,可以减少添加糖的含量并减少相应的热量,还能保持甜味,但这项最新研究表明,一些人造甜味剂与癌症风险增加有关

许多含有人造甜味剂的食品和饮料每天被数百万人食用。然而,这些添加剂的安全性一直是争论的主题。

为了评估人造甜味剂的潜在致癌性,研究团队分析了参与 NutriNet-Santé 研究的 102865 名法国成年人的数据。NutriNet-Santé 研究是由营养流行病学研究小组(EREN)于 2009 年发起的一项正在进行的基于网络的队列研究。参与者自愿报名,并自行报告病史、社会人口学、饮食、生活方式和健康数据。

研究团队从24小时饮食记录中收集了有关人造甜味剂摄入量的数据。在随访期间收集癌症诊断信息后,进行了统计分析,以调查人造甜味剂摄入量与癌症风险之间的关联。

研究团队调整了一系列变量,包括年龄、性别、教育、体育活动、吸烟、体重指数、身高、随访期间的体重增加、糖尿病、癌症家族史,以及能量、酒精、钠、饱和脂肪酸、纤维、糖、全麦食品和乳制品的基线摄入量。

研究人员发现,与不食用人造甜味剂的人相比,摄入大量人造甜味剂,尤其是阿斯巴甜和安赛蜜的参与者整体癌症风险更高(风险比为1.13,95%置信区间为1.03至1.25)。其中乳腺癌和肥胖相关癌症的风险更高。

该研究有几个重要的局限性;膳食摄入量是自我报告的。选择偏见也可能是一个因素,因为参与者更有可能是女性,具有更高的教育水平,并表现出健康意识的行为。该研究的观察性质也意味着可能存在残余混杂,不能排除反向因果关系。需要进一步的研究来证实这些发现并阐明潜在的机制。

研究团队表示,这项研究结果提示了使用人造甜味剂作为食品或饮料中糖的替代品并非我们之前认为的那么安全,也为食品添加剂甜味剂的重新评估提供了重要而新颖的见解。

原始出处:

Charlotte Debras, et al. Artificial sweeteners and cancer risk: Results from the NutriNet-Santé population-based cohort study. PLOS Medicine, 2022.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-09-02 jeanqiuqiu
  2. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2023-02-23 kalseyzl
  4. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-05-10 ylz8403
  5. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1859243, encodeId=274d1859243e7, content=<a href='/topic/show?id=e0a9593596' target=_blank style='color:#2F92EE;'>#DIC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5935, encryptionId=e0a9593596, topicName=DIC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7770, createdName=jeanqiuqiu, createdTime=Fri Sep 02 09:35:18 CST 2022, time=2022-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1708155, encodeId=8c7a1e0815516, content=<a href='/topic/show?id=e00b251e5dc' target=_blank style='color:#2F92EE;'>#人造#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25175, encryptionId=e00b251e5dc, topicName=人造)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48aa31545372, createdName=zjshifan_98647316, createdTime=Sat Jul 30 13:35:18 CST 2022, time=2022-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1774042, encodeId=990d1e7404214, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Feb 23 22:35:18 CST 2023, time=2023-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043483, encodeId=6566204348359, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Tue May 10 15:35:18 CST 2022, time=2022-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1577880, encodeId=f02415e7880b1, content=<a href='/topic/show?id=cda91148004' target=_blank style='color:#2F92EE;'>#Medicine#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11480, encryptionId=cda91148004, topicName=Medicine)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=54cd16396700, createdName=ms1692212821629096, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611515, encodeId=05a8161151550, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Mar 28 13:35:18 CST 2022, time=2022-03-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206545, encodeId=24a712065459d, content=安赛蜜,阿斯巴甜, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=969d2873055, createdName=走,走走, createdTime=Mon Mar 28 08:53:53 CST 2022, time=2022-03-28, status=1, ipAttribution=)]
    2022-03-28 走,走走

    安赛蜜,阿斯巴甜

    0

相关资讯

蜘蛛丝增强p53抗癌能力,有望开发出广谱mRNA癌症疫苗

p53是一个拥有广泛而强大功能的抑癌基因,超过一半的肿瘤患者带有p53基因突变。p53基因突变是肿瘤发生、发展、治疗耐药性和预后不良的重要驱动力。

JNCC:赫捷院士团队发布中国全新癌症数据:肺癌是中国常见及死亡人数最多的癌症

中国的癌症负担很重,预计未来十年还会继续增加。中国出台了一系列卫生政策,优先推进癌症防治工作。

J Clin Oncol:癌症患儿、医生、监护人报告的癌症治疗的不良反应的差异性

医生评估的不良反应等级往往低于患儿报告的,监护人报告的又常高于患儿报告的

JAMA 子刊:90%以上的癌症患者, COVID-19 疫苗接种后产生抗体!

血液肿瘤患者和正在接受免疫抑制治疗的患者可能需要优先接种第三剂疫苗,并仔细考虑相对于接受癌症治疗的疫苗接种时间。

因小区封闭癌症患者治疗难 上海发布:已安排患者去大华医院

目前相关部门已安排肿瘤医院周边封控小区需要化疗的病人去大华医院做置管维护。

JNCC:赫捷院士团队发布中国全新癌症发生率和死亡率数据

赫捷院士为通讯作者在JNCC发表题为《Cancer Incidence and Mortality in China,2016》的文章。该研究基于国家癌症中心最新数据,从全国682个癌症监测点中遴选4